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Background: Adherence to therapy is a key require-
ment underlying achievement of clinical outcomes in
randomized controlled drug registration trials. In
postmarketing studies, comparison of adherence
among therapies can become more complicated when
drug dosing and administration schedules differ or
when methods used to measure adherence are not
consistently applied.
Objective: The objective of this exploratory study
was to investigate a broad range of utilization and
adherence outcomes associated with subcutaneous
biologic treatments for rheumatoid arthritis (RA).
Methods: Adult patients (aged Z18 years) exhibit-
ing Z2 claims with an RA diagnosis (code 714.x), at
least 24 months of continuous medical and pharmacy
eligibility, and 30-day supplies of adalimumab, eta-
nercept, or golimumab were selected from the Optum
Insight Clinformatics database. Adherence and uti-
lization measures were calculated and compared
across treatment groups.
Results: A total of 1532 adalimumab, 2099 etaner-
cept, and 261 golimumab patients met inclusion criteria.
Compared with both adalimumab and etanercept pa-
tients, golimumab patients were signiﬁcantly more likely
to have a medication possession ratio ofZ0.80 (82% vs
71% vs 62%; Po 0.001) and signiﬁcantly less likely to
have Z4 late medication reﬁlls (6.9% vs 17.7% vs
26.1%; P o 0.001 for all). Etanercept patients had
signiﬁcantly greater reﬁll intervals (37.7 vs 34.9 and
35.1 days) and had the lowest proportion of adherent
ﬁlls (70% vs 77% and 75%) compared with both
golimumab and adalimumab patients (P o 0.001 for
all). Bivariate effects were reproduced in multivariate
models that controlled for treatment duration.
Conclusions: A number of statistically signiﬁcant
medication adherence differences were observedMay 2014among golimumab, adalimumab, and etanercept pa-
tients in treatment for RA. Overall, golimumab
patients appeared to be the most adherent group.
Findings may be partially attributable to golimumab
patients’ likely increased disease severity, their prior
experience with biologic medication, or golimumab’s
once-monthly dosing schedule, which requires fewer
administrations than both adalimumab and etaner-
cept. (Clin Ther. 2014;36:737–747) & 2014 The
Authors. Published by Elsevier HS Journals, Inc.
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Open access under CC BY-NC-ND license.Rheumatoid arthritis (RA) is an autoimmune disease
that affects 1% of the global population and is
characterized by an inﬂammation of the joints and
surrounding tissues.1 During the past decade, the
treatment of RA has improved signiﬁcantly with the
development of a variety of biologic agents target-
ing tumor necrosis factor (TNF).2 As a result, the
use of these agents has signiﬁcantly increased as
either monotherapy or combination therapy with
nonbiologic disease-modifying antirheumatic drugs
(DMARDs).3 Despite increased utilization, patient
adherence to biologic agent use remains unclear.4
Adherence, typically deﬁned as the degree to
which a medication is taken as prescribed, encom-
passes dosage, timing, and frequency.5 A number of
recent reviews have highlighted the inconsistent
reporting of adherence to biologic treatments,4,6,7737
Clinical Therapeuticsobfuscating any attempt to evaluate and compare the
real-world cost or clinical beneﬁts of these agents.
For example, one investigation of biologic-treated
Medicaid enrollees deﬁned 1-year adherence as a
proportion of days covered (PDC) of Z80%, which
resulted in 1-year adherence rates of 11% for
anakinra patients, 32% for etanercept patients, and
43% for inﬂiximab patients.8 Similarly, another
investigation measured adherence using the
medication possession ratio (MPR) of Z80% but
reported much higher rates of adherence: 63% for
new etanercept patients and 65% for new
adalimumab patients.9 Brocq et al10 focused on
1-year drug continuation rates and reported rates
of 87% for etanercept users, 83% for adalimumab
users, and 68% for inﬂiximab users. As these results
indicate, current estimates of biologic therapy ad-
herence vary considerably across methods, ranging
from 11% to 87%, which can be directly attribut-
able to a lack of uniformity in deﬁning and calculat-
ing speciﬁc adherence outcomes. An analysis
examining a broader range of treatment measures
related to patient adherence may serve to ameliorate
this issue.
Adalimumab,11 etanercept,12 and golimumab13 are
3 anti-TNF biologic agents currently approved for the
treatment of RA. Each of these medications is admin-
istered via subcutaneous injection and has been
reported to be effective in the treatment of RA,14–17
although each has a unique formulation and dosing
schedule. The purpose of this exploratory study was
to investigate a number of utilization measures asso-
ciated with adalimumab, etanercept, and golimumab
treatment, including dosing, reﬁll intervals, and multi-
ple proxies of adherence, and to compare ﬁndings
across treatment groups.
METHODS
Sample Selection
Study data were derived from the Optum Insight
Clinformatics database of insured individuals. Data
were completely void of identifying information.
Medical, pharmacy, and laboratory claims for mem-
bers with a rheumatic disease diagnosis during quarter
4 of calendar year 2005 through quarter 1 of 2012
were studied. Figure 1 details the study inclusion and
exclusion criteria and the sample size remaining after
each exclusion criterion imposition. To be eligible for
this study, members were required to receive738treatment with a biologic during the case ﬁnding
window: January 1, 2009 through March 31, 2011.
Members were retained for analyses if their most
recent biologic on record was either adalimumab,
etanercept, or golimumab, with the earliest ﬁll for
that particular biologic serving as the study index
date. Members treated with certolizumab were
initially considered to be included in this study,
although they were eventually excluded due to
underrepresentation relative to other groups (n ¼ 80
[3% of ﬁnal sample]). This approach ensured that
representation of patients was maximized for
biologics such as golimumab, which indicated a
lower overall prevalence in the data set. All members
were required to have at least 2 years of continuous
eligibility: 1 year before and 1 year after the index
date. Members were also required to have at least 2
claims for rheumatoid arthritis (code 714.x) within 1
year of the index date and no diagnoses of ankylosing
spondylitis (code 720.x) or psoriatic arthritis (code
696.x) within that same period. All members must
have been at least 18 years of age, and women must
not have been pregnant at any time during the study.
In addition, members with a comorbid diagnosis of
Crohn disease (code 555.x) were excluded because
this is an approved indication for adalimumab.11
Because most patients received 30-day supplies of
medication (68%), to minimize artifacts, only those
members with 30-day supply ﬁlls of their index
medication across their episode of care were main-
tained for ﬁnal analyses. After the imposition of all
inclusion and exclusion criteria, the ﬁnal sample size
was 3892 (n ¼ 1532 for the adalimumab group, n ¼
2099 for the etanercept group, and n ¼ 261 for the
golimumab group).
Measures
Patient demographic characteristics were summar-
ized from the membership table and included age, sex,
geographic region of residence, insurance line of
business, and type of beneﬁt plan. In addition, the
Charlson Comorbidity Index, an overall measure of
health,18 was calculated during the 1-year preindex
period, as were the rates for a variety of other
comorbidities of interest. Prior biologic utilization
during the 1-year preindex period was also
calculated.
The following section outlines the primary treat-
ment outcomes, which were calculated for allVolume 36 Number 5
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Figure 1. Sample attrition. *Starting sample consisted of members with a single diagnosis of rheumatoid
arthritis, ankylosing spondylitis, or psoriatic arthritis between quarter 4 of 2005 and quarter 1
of 2012.
J. Tkacz et al.members who qualiﬁed for the analyses. All treatment
outcomes were derived from the pharmacy claims
table and were calculated for the period the patient
continued to take their assigned study medication.
Patients were followed up until discontinuation or
until a period ofZ90 days without a ﬁll for the index
medication was observed. Patients were followed up
for longer than 1 year if they maintained eligibility
and continually received treatment (ie, did not have
evidence of a lapse in treatment).
Adalimumab, etanercept, and golimumab treat-
ment ﬁlls were identiﬁed via brand name and were
summed for each member. The corresponding days’May 2014supply value for these treatments was also summed by
member. The MPR was calculated by summing the
days’ supply value of the index treatment and dividing
this amount by the duration of treatment, which was
the sum of days between the index date and the most
recent index treatment ﬁll plus the days’ supply value
of the last ﬁll.19 The MPR values 41 were recoded
into 1, and the proportion of patients with an MPR
Z0.60 and Z0.80 were reported. The PDC was also
calculated, which is another measure of days in which
medication was on hand, but adjusts for double-
counting of covered days.19 As with MPR, the
proportion of patients with a PDC Z0.60 and739
Clinical TherapeuticsZ0.80 were reported. Medication dosages were
extracted from the strength ﬁeld, and mean patient
dosages were calculated. Similarly, mean reﬁll
intervals were also calculated for each patient, in
addition to summing the total number of early, late,
and adherent ﬁlls. An adherent ﬁll interval was deﬁned
as a reﬁll appearing Z21 and r38 days from the
previous ﬁll. A reﬁll interval of r15 days was
categorized as early, whereas a reﬁll interval Z45
days was categorized as late.
Statistical Analyses
Bivariate group comparisons were initially con-
ducted for all demographic and treatment measures.
χ2 tests of equality of proportions were used for
categorical variables, and 1-way analysis of variance
was used for continuous variables. Turkey’s post hoc
tests were conducted to examine group differences
where omnibus test results were statistically signiﬁ-
cant. Outcomes that resulted in statistically signiﬁcant
bivariate group effects were entered into multivariate
analyses that controlled for demographic character-
istics, health status, and treatment duration.
Ordinary least squares regression models were used
for continuous variables, while dichotomous, catego-
rical variables were regressed onto predictors via
logistic models. The golimumab group served as the
reference treatment category in all models. Data
management and analyses were conducted using SPSS
statistical software, version 20 (SPSS Inc, Chicago,
Illinois).
RESULTS
Members were predominantly female, (75.5%), with a
mean (SD) age of 51.1 (11.2) years, residing predom-
inantly in the mid-American (39.0%) and Southeast-
ern (39.0%) regions of the United States. Nearly the
entire sample was commercially insured (99.5%), with
most holding a point-of-service beneﬁt package
(69.1%). The mean (SD) Charlson Comorbidity Index
score was 0.52 (0.95). Table I lists the demographic
characteristics by treatment group. Golimumab
members were 43 times as likely to evidence prior
biologic exposure as adalimumab members and 46
times as likely as etanercept members (P o 0.001 for
all). Nearly 60% of the golimumab group had
previous experience with a biologic. The most
commonly used prior biologic for adalimumab
members was etanercept (12.3%), with adalimumab740(6.1%) being the most commonly used for etanercept
members. Golimumab members also tended to have
the highest comorbid disease burden of the 3 groups,
evidenced by a signiﬁcantly higher proportion with a
diagnosis of depression, osteoarthritis, chronic pain,
cerebrovascular disease, and hypertension compared
with both the adalimumab and etanercept groups
(P o 0.05 for all). Both the golimumab and
etanercept groups had a signiﬁcantly higher mean
Charlson Comorbidity Index score than the
adalimumab patients (P o 0.05). There were no
statistically signiﬁcant treatment group differences
for the remaining demographic indicators.
Table II gives the group descriptive statistics and
results of bivariate comparisons for the primary
treatment outcomes. Compared with both the
adalimumab and golimumab groups, the etanercept
group had a signiﬁcantly greater number of ﬁlls (19.4
vs 18.3 vs 13.1) and cumulative days’ supply of
treatment (546 vs 516 vs 384), whereas the
adalimumab group had signiﬁcantly greater ﬁlls and
days’ supply than the golimumab group (P o 0.001
for all). All 3 groups signiﬁcantly differed from each
other on both the MPR and PDC measures, with the
golimumab group (MPR ¼ 0.88, PDC ¼ 0.87) having
signiﬁcantly higher values than both the adalimumab
(MPR ¼ 0.85, PDC ¼ 0.84) and etanercept groups
(MPR ¼ 0.81, PDC ¼ 0.81) and with the adalimumab
group having signiﬁcantly higher values than the
etanercept group (P o 0.001 for all). The same
pattern of results was obtained when groups were
compared on the proportion with MPR and PDC
values Z0.80 (P o 0.001 for all). Further, compared
with the etanercept group, the golimumab and
adalimumab groups evidenced signiﬁcantly shorter
reﬁll intervals (34.9 and 35.1 vs 37.7 days) and a
higher mean proportion of treatment ﬁlls categorized
as adherent (77% and 75% vs 70%; P o 0.001 for
all). Groups did not signiﬁcantly differ on the
proportion with an early reﬁll, but compared with
the adalimumab and etanercept groups, the
golimumab group was signiﬁcantly less likely to have
at least 1 late reﬁll (62.8% vs 71.5% and 74.4%).
Further, the golimumab group was signiﬁcantly less
likely to have Z4 late reﬁlls compared with both the
adalimumab and etanercept groups, whereas the
adalimumab group was signiﬁcantly less likely than
the etanercept group (6.9% vs 17.7% vs 26.1%; P o
0.001 for all).Volume 36 Number 5
Table I. Patient demographic characteristics.
Characteristic
No. (%) of Patients*
P
Adalimumab
(n ¼ 1532)
Etanercept
(n ¼ 2099)
Golimumab
(n ¼ 261)
Female 1157 (75.5) 1572 (74.9) 211 (80.8) 0.108
Geographic region 0.082
Mid-American 600 (39.2) 824 (39.3) 93 (35.6)
Northeast 86 (5.6) 163 (7.8) 16 (6.1)
Southeast 619 (40.4) 798 (38.0) 102 (39.1)
West 227 (14.8) 314 (15.0) 50 (19.2)
Beneﬁt plan business type 0.475
Commercial 1524 (99.5) 2087 (99.4) 261 (100.0)
Medicaid 8 (0.5) 12 (0.6) 0
Medicare 0 0 0
Type of beneﬁt plan 0.026
EPO 229 (14.9) 325 (15.5) 44 (16.9)
HMO 163 (10.6) 211 (10.1) 22 (8.4)
IND 15 (1.0) 46 (2.2) 2 (0.8)
OTH 1 (0.1) 5 (0.2) 0
POS 1073 (70.0) 1441 (68.7) 176 (67.4)
PPO 51 (3.3) 71 (3.4) 17 (6.5)
Age, y 0.176
Mean (SD) 50.7 (11.0) 51.4 (11.4) 50.6 (10.6)
Median 52 53 52
Patients o65 years old 1435 (93.7) 1932 (92.0) 246 (94.3) 0.113
Prior biologics use
Any prior biologic use†,‡,§ 249 (16.3) 187 (8.9) 155 (59.4) o0.001
1 Prior treatment 236 (15.4) 174 (8.3) 129 (49.4)
2 Prior treatments 13 (0.8) 13 (0.6) 23 (8.8)
3 Prior treatments 0 3 (1.1)
Speciﬁc treatments
Golimumab 9 (0.6) 6 (0.3)
Adalimumab 128 (6.1) 62 (23.8)
Etanercept 189 (12.3) 64 (24.5)
Abatacept 18 (1.2) 20 (1.0) 26 (10.0)
Inﬂiximab 34 (2.2) 37 (1.8) 20 (7.7)
Certolizumab 6 (0.4) 2 (0.1) 6 (2.3)
Anakinra 3 (0.2) 0 0
Rituximab 3 (0.2) 7 (0.3) 6 (2.3)
Tocilizumab 0 0 0
None 1283 (84.6) 1912 (92.0) 106 (39.5)
Select preperiod comorbidities
Cerebrovascular disease†,‡ 41 (2.7) 56 (2.7) 14 (5.4) 0.041
Chronic renal disease 20 (1.3) 43 (2.0) 8 (3.1) 0.077
Diabetes (without complications) 127 (8.3) 199 (9.5) 29 (11.1) 0.240
(continued)
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Table I. (continued).
Characteristic
No. (%) of Patients*
P
Adalimumab
(n ¼ 1532)
Etanercept
(n ¼ 2099)
Golimumab
(n ¼ 261)
Disorders of lipid metabolism 501 (32.7) 696 (33.2) 97 (37.2) 0.365
Depression†,‡ 162 (10.6) 197 (9.4) 41 (15.7) 0.006
Osteoarthritis†,‡ 849 (55.4) 1138 (54.2) 165 (63.2) 0.022
Chronic pain†,‡ 58 (3.8) 73 (3.5) 25 (9.6) o0.001
Hypertension†,‡ 512 (33.4) 707 (33.7) 110 (42.1) 0.018
Charlson Comorbidity Index score, mean (SD)†,§ 0.47 (0.86) 0.54 (0.99) 0.59 (1.10) 0.023
EPO ¼ exclusive provider organization; HMO ¼ health maintenance organization; IND ¼ indemnity; OTH ¼ other; POS ¼
point of service; PPO ¼ preferred provider organization.
*Data are presented as number (percentage) of patients unless otherwise indicated.
†Simponi a adalimumab.
‡Simponi a etanercept.
§Adalimumab a etanercept.
Clinical TherapeuticsTable III and Table IV give the results of ordinary
least squares and logistic models of treatment
outcomes that controlled for treatment duration and
patient characteristics. Men received signiﬁcantly
more ﬁlls and days’ supply of treatment compared
with women and were more adherent as measured by
both the MPR and PDC (P o 0.05 for all). Age was
positively associated with treatment ﬁlls, days’ supply,
MPR, and PDC but inversely related with mean reﬁll
interval (P o 0.05 for all). Treatment duration was
positively associated with all outcomes, excluding the
numeric MPR value (P o 0.05 for all). Health status,
as measured by the Charlson Comorbidity Index, and
geographic region of residence did not relate to any
treatment outcomes (P 4 0.05 for all).
As for the main predictor of interest, treatment
group, most bivariate effects were reproduced in multi-
variate models. Adalimumab members were only half
as likely as golimumab members to achieve an MPR or
PDC Z0.80, whereas etanercept members were only
one-third as likely (P o 0.01 for all). Both the
adalimumab and etanercept groups had signiﬁcantly
greater mean reﬁll intervals than the golimumab group
(P o 0.05), with etanercept members being more than
twice as likely as golimumab members to haveZ4 late
reﬁlls (P ¼ .001). Finally, both the adalimumab and
etanercept members were signiﬁcantly less likely to
have prior biologic exposure (P o 0.001 for all).742DISCUSSION
The objectives of the present study were to examine
utilization and adherence measures for 3 subcutane-
ously administered anti-TNF agents indicated for the
treatment of RA (adalimumab, etanercept, and goli-
mumab) and to compare treatment outcomes across
groups. Golimumab comprised the smallest study
group, accounting for only 7% of the overall sample,
with the adalimumab (39%) and etanercept (54%)
groups making up most of patients. Overall, the
sample appeared to be receiving treatment within
recommended prescribing guidelines because mean
dosages and reﬁll intervals approximated expected
values. In addition, multiple adherence measures were
assessed during the study period. Data were adequate
because most of the sample received treatment for41
year and evidenced elevated values for both the MPR
and PDC. Interestingly, numerous treatment utiliza-
tion and adherence differences were found across the
study groups.
Etanercept use was the most prevalent of the 3
biologics studied, whereas golimumab utilization was,
as expected, the lowest because it was the latest to be
approved and the last commercially available of the 3
agents. Golimumab patients had signiﬁcantly higher
rates of medication adherence as measured by the
MPR and PDC compared with both adalimumab and
etanercept patients and were also less likely to haveVolume 36 Number 5
Table II. Treatment outcomes.
Outcome
No. (%) of Patients*
P
Adalimumab
(n ¼ 1532)
Etanercept
(n ¼ 2099)
Golimumab
(n ¼ 261)
Total ﬁlls 28,058 (100.0) 40,701 (100.0) 3409 (100.0)
Fills per member, mean (SD)†,‡,§ 18.3 (11.9) 19.4 (12.0) 13.1 (7.8) o0.001
Total days’ supply, mean (SD)†,‡,§ 516 (334) 546 (338) 384 (230) o0.001
MPR, mean (SD)†,‡,§ 0.85 (0.13) 0.81 (0.15) 0.88 (0.11) o0.001
MPR Z0.80†,‡,§ 1080 (70.5) 1298 (61.8) 214 (82.0) o0.001
MPR Z0.60‡,§ 1435 (93.7) 1861 (88.7) 252 (96.6) o0.001
PDC, mean (SD)†,‡,§ 0.84 (0.13) 0.81 (0.15) 0.87 (0.10) o0.001
PDC Z0.80 1073 (70.0) 1284 (61.2) 212 (81.2) o0.001
PDC Z0.60†,‡,§ 1432 (93.5) 1860 (88.6) 252 (96.6) o0.001
Patient dose, mean (SD), mg‡,§ 87.0 (20.2) 193.3 (24.7) 52.2 (10.5)
Patient reﬁll interval, mean (SD), d‡,§ 35.1 (9.3) 37.7 (12.0) 34.9 (8.0) o0.001
Patient proportion of adherent ﬁlls, mean (SD)‡,§ 0.75 (0.24) 0.70 (0.28) 0.77 (0.23) o0.001
Early reﬁll 47 (3.1) 55 (2.6) 8 (3.1) 0.703
Late reﬁll†,‡ 1095 (71.5) 1561 (74.4) 164 (62.8) o0.001
Z4 Late reﬁlls†,‡,§ 271 (17.7) 547 (26.1) 18 (6.9) o0.001
MPR ¼ medication possession ratio; PDC ¼ proportion of days covered.
*Data are presented as number (percentage) of patients unless otherwise indicated.
†Golimumab a adalimumab.
‡Golimumab a etanercept.
§Adalimumab a etanercept.
J. Tkacz et al.multiple, late reﬁlls. The golimumab group was also
the most experienced with biologic medication, with
nearly 60% of this group having prior treatment with
a biologic, nearly 5 times greater than adalimumab
and etanercept patients. Golimumab and adalimumab
patients both had briefer reﬁll intervals and a higher
percentage of adherent ﬁlls compared with etanercept
patients. Group effects were maintained in multi-
variate models that controlled for the duration of
therapy and patient characteristics, indicating that
these group differences do not account for differences
in adherence measures.
Overall, golimumab patients appeared to be the most
adherent group during the study period, despite having
the poorest overall health. This is the ﬁrst known study
to report greater real-world adherence for golimumab
compared with 2 established biologics. Differences in
clinical effectiveness across adalimumab, etanercept,
and golimumab have not been studied directly,
although the approval of these agents was basedMay 2014on meeting similar primary outcomes in clinical tri-
als.20–22
There are a number of plausible interpretations of
the present results. Golimumab was the only biologic
agent in the present study with a once-monthly dosing
schedule. Multiple studies of adherence across a
variety of medication classes have reported the inverse
relationship between dosing frequency and adher-
ence,23–25 and patients have been found to prefer
longer vs shorter dosing intervals when given the
option.26–28 In the present study, this relationship
appeared evident for a number of adherence measures,
including the MPR, PDC, and proportion with Z4
late reﬁlls, because patients treated with once-monthly
golimumab evidenced signiﬁcantly improved out-
comes on these measures compared with bimonthly
treated adalimumab patients, who in turn evidenced
signiﬁcant improvements compared with weekly-
treated etanercept patients. In addition, increased
medication adherence has been associated with743
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744increased disease severity,29 and although disease
severity cannot be accurately measured in claims
data alone, the golimumab group’s increased rate of
both prior biologic use and overall number of
comorbidities indicate a potentially more severe
disease state. Further, the belief that medication is
necessary for disease treatment is also a positive
predictor of adherence,30 and the golimumab
group’s increased prior exposure to biologic
treatment compared with the other groups may have
strengthened their belief in the medical necessity of the
current treatment regimen. Regardless, results suggest
golimumab may be the ideal treatment option for
patients with difﬁculty maintaining adherence, al-
though ﬁndings should be replicated in a biologic-
naive sample to solidify the relationship between
golimumab treatment and adherence.
Although there is evidence suggesting that adher-
ence to biologic medication is less than optimal,31
which may be partly due to inconsistent reporting and
deﬁning of relevant measures as discussed in the
opening of the article, results of the present study
revealed generally positive adherence outcomes for all
3 treatment groups. Adherence has been linked to
improved outcomes across a variety of chronic
diseases states,32 including RA.33,34 In addition, per-
sistence to biologic therapy among RA patients has
also been associated with a reduction in non–phar-
macy-related health care expenditure.35 Further study
of RA patient motivation toward treatment adherence
is needed, particularly for biologics. A number of
factors related to improved medication adherence
have previously been identiﬁed in RA patients,
including a satisfactory level of patient-physician
communication, an increased knowledge of RA in
general, and older age,36 whereas nonwhite race and
low educational level have been found to be related to
decreased adherence.37 In addition, studies have found
that patients typically prefer subcutaneous injection
over intravenous and intramuscular injections,38,39
which may promote adherence in itself. A better
understanding of the drivers of treatment adherence
may reduce the amount of time patients spend on
ineffective treatments and, given the higher expenses
typically associated with biologic treatment,40,41 may
have signiﬁcant economic implications. Given the
increasing amount of clinical and economic data being
collected in health care today, these data can be used
to promote a patient-centered model of care in whichVolume 36 Number 5
Table IV. Multivariate analyses of treatment outcomes in logistic models.
Predictor
MPR Z0.80 PDC Z0.80 Z4 Late Reﬁlls
Prior Biologic
Exposure
β
Exp
(B) P β
Exp
(B) P β
Exp
(B) P β
Exp
(B) P
Adalimumab 0.72 0.49 o0.01 0.69 0.50 o0.01 0.45 1.57 0.09 1.90 0.15 o0.01
Etanercept 1.16 0.31 o0.01 1.14 0.32 o0.01 0.85 2.34 o0.01 2.55 0.08 o0.01
Male 0.20 1.22 0.02 0.20 1.22 0.02 0.33 0.72 o0.01 0.12 0.88 0.28
Age 0.03 1.03 o0.01 0.02 1.02 o0.01 0.03 0.97 o0.01 0.01 0.99 0.09
Charlson Comorbidity
Index score
0.06 1.06 0.12 0.07 1.07 0.09 0.04 1.04 0.39 0.05 1.05 0.37
Treatment duration 0 1.00 o0.01 0 1.00 o0.01 0 1.00 o0.01 0 1.00 o0.01
Mid-American region 0.01 0.99 0.93 0.03 1.03 0.84 0.02 1.02 0.90 0.13 0.88 0.50
Southeast region 0.04 0.96 0.77 0.04 0.96 0.80 0.10 1.10 0.61 0.30 0.74 0.12
West region 0.03 0.97 0.84 0 1.00 0.98 0.17 1.19 0.39 0.19 0.83 0.38
Constant 0.07 1.08 0.78 0.03 1.03 0.90 2.97 0.05 0 1.38 3.97 0
MPR ¼ medication possession ratio; PDC ¼ proportion of days covered.
J. Tkacz et al.much improved disease management is possible.42
Analyses similar to those appearing in the present
study can be used by prescribers to monitor patient
treatment adherence, in addition to health plans for
purposes of avoiding unnecessary spend.
The present study has a number of limitations. The
primary limitation is the potential endogeneity of the
between-groups factor (treatment), meaning that there
could be other unmeasured factors that drive utilization
and adherence patterns associated with each medica-
tion. Treatment groups were not matched to variations
in patient characteristics among the groups, and data
have indicated that differences in these factors may
confound study conclusions. Although multivariate
models that control for patient characteristics were
conducted, an analysis using propensity score matching
or instrumental variables may be of some utility. An
additional limitation was the data source (administra-
tive claims data), which does not allow for the assess-
ment of clinical outcomes related to adherence and may
also include administrative coding errors.43 Finally, the
MPR and PDC were calculated based on the length of
each individual patients’ treatment episode, as opposed
to a ﬁxed interval (eg, 1 year). Given the cycling-for-
remission strategy used in RA biologic treatment,44 use
of a ﬁxed interval can result in a deﬂated estimate ofMay 2014adherence because patients may adhere for a period
only to discontinue use shortly thereafter because of
ineffectiveness or adverse effects.
In conclusion, the dosing and scheduling complex-
ities of biologic treatment have been found to be
problematic for the standardized measurement and
assessment of medication adherence. The present
study was designed to measure multiple indicators of
biologic administration process indicators among a
sample of RA patients treated with subcutaneously
administered anti-TNFs. Adalimumab, etanercept,
and golimumab patients were found to be generally
adherent with their treatment regimens because dos-
ages and reﬁll intervals were in agreement with
recommended prescribing guidelines and proxies for
medication adherence were in the appropriate range.
Utilization of golimumab was signiﬁcantly lower than
that of adalimumab and etanercept, although golimu-
mab patients appeared to be the most adherent during
their treatment despite also being in the poorest
overall health. Speciﬁcally, golimumab patients had
signiﬁcantly higher MPRs and PDCs compared with
the adalimumab and etanercept patients and were also
less likely to have multiple, late reﬁlls. The favorable
adherence results achieved by the golimumab group
may be a result of these patients’ likely increased745
Clinical Therapeuticsdisease severity, their prior experience with biologic
medication, or golimumab’s once-monthly dosing
schedule. Overall, study ﬁndings were encouraging
but indicate the need for additional comparative
effectiveness studies between golimumab and the
established biologics to conﬁrm adherence results
and to quantify the precise clinical and economic
beneﬁts associated with biologic adherence.
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